Putative vacuolar protein sorting-associated protein 60
Glycylpeptide N-tetradecanoyltransferase
Helical; Signal-anchor for type II membrane protein
Charge relay system; for autoendoproteolytic cleavage activity
Phosphatidylserine decarboxylase alpha chain
Phosphatidylserine decarboxylase beta chain
Schiff-base intermediate with substrate; via pyruvic acid; for decarboxylase activity
Structural maintenance of chromosomes protein 3 homolog
Putative chloroquine resistance transporter
Dihydrolipoamide acetyltransferase component of pyruvate dehydrogenase complex
Queuine tRNA-ribosyltransferase-like protein
Merozoite surface protein P12, processed form
30% reduction in catalytic activity. Slight decrease in heme binding.
50% reduction in catalytic activity. 50% reduction in catalytic activity; when associated with A-44, A-58, A-70, A-79, A-122, A-172, A-175 and A-192.
50% reduction in catalytic activity. 50% reduction in catalytic activity; when associated with A-44, A-58, A-70, A-79, A-122, A-172, A-192 and A-197.
50% reduction in catalytic activity. 50% reduction in catalytic activity; when associated with A-44, A-58, A-70, A-79, A-122, A-175, A-192 and A-197.
50% reduction in catalytic activity. 50% reduction in catalytic activity; when associated with A-44, A-58, A-70, A-79, A-172, A-175, A-192 and A-197.
60% reduction in catalytic activity. Decreases heme binding.
No effect on catalytic activity. 50% reduction in catalytic activity; when associated with A-44, A-58, A-70, A-122, A-172, A-175, A-192 and A-197.
No effect on catalytic activity. 50% reduction in catalytic activity; when associated with A-44, A-58, A-70, A-79, A-122, A-172, A-175 and A-197.
No effect on catalytic activity. 50% reduction in catalytic activity; when associated with A-44, A-58, A-79, A-122, A-172, A-175, A-192 and A-197.
No effect on catalytic activity. 50% reduction in catalytic activity; when associated with A-44, A-70, A-79, A-122, A-172, A-175, A-192 and A-197.
No effect on catalytic activity. 50% reduction in catalytic activity; when associated with A-58, A-70, A-79, A-122, A-172, A-175, A-192 and A-197.
Malarial early transcribed membrane protein (ETRAMP)
Uncharacterized J domain-containing protein PF3D7_1401100
Putative E3 ubiquitin-protein ligase protein PFF1365c
Schiff-base intermediate with acetaldehyde
Merozoite surface protein P41, processed form
Phosphatidylinositol 4-phosphate 5-kinase
Translationally-controlled tumor protein homolog
AP2/ERF domain-containing protein PFD0985w
Complete loss of deubiquitinating and deneddylating activities.
No defect in parasite growth in host erythrocytes. Severe loss of deneddylating activity with no effect on deubiquitinating activity; when associated with 251-K--M-295 DEL.
No effect on deubiquitinating activity. Slight increase in deneddylating activity. Severe loss of deneddylating activity with no effect on deubiquitinating activity; when associated with E-38. No effect on deubiquitinating and deneddylating activities; when associated with D-18.
No effect on deubiquitinating and deneddylating activities; when associated with 251-K--M-295 DEL.
Ubiquitin carboxyl-terminal hydrolase UCH54
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1
Cysteine sulfenic acid (-SOH) intermediate; for peroxidase activity
Plasmodium yoelii subtelomeric region (PYST-C1)
Conditional deletion at the beginning of the first erythrocyte infection cycle results in no defect in egress and subsequent invasion. However, in the next invasion cycle, causes a severe growth defect and developmental arrest between the ring and trophozoite stages. Export of HRP2 into the host erythrocyte is also partially impaired.
Loss of catalytic activity. Loss of catalytic activity; when associated with A-365 or A-365 and A-370.
Loss of catalytic activity; when associated with A-118 and A-365.
Loss of catalytic activity; when associated with A-118 or A-118 and A-370.
7-fold reduction in affinity for adenosine and 9-fold reduction in affinity for 5'-methylthioadenosine. Reduces further catalytic efficiency with adenosine or 5'-methylthioadenosine as substrates; when associated H-179.
No effect on catalytic activity towards adenosine or 5'-methylthioadenosine; when associated with I-227.
No effect on catalytic activity towards adenosine or 5'-methylthioadenosine; when associated with Q-27.
No effect on catalytic activity. Reduces further catalytic efficiency with adenosine or 5'-methylthioadenosine as substrates; when associated A-176.
Severe decrease in catalytic activity towards adenosine or 5'-methylthioadenosine.
Severe reduction in catalytic efficiency with adenosine or 5'-methylthioadenosine as substrates.
Slight decrease in affinity for adenosine and severe reduction in affinity for 5'-methylthioadenosine.
Slight increase in affinity for adenosine and severe reduction in affinity for 5'-methylthioadenosine.
Loss of the first autocatalytic maturation cleavage. Impaired microneme localization and accumulation in a ER-like secretory compartment.
Mitochondrial inner membrane magnesium transporter MIT1
Loses the ability to form the reaction intermediate lipoyl-AMP resulting in a loss of catalytic activity. Abolishes lipoylation of GCVH/H-protein. Abolishes lipoylation of BCKDH-E2/BCDH and KDH in the presence of LipL2.
Signal peptidase complex catalytic subunit SEC11
Dolichol-phosphate mannosyltransferase subunit 1
50% reduction in activity with Zn(2+) as cofactor. Increases activity with Co(2+) as cofactor and acquires new substrate specificity to leucine, tryptophan and phenylalanine.
Cofilin/actin-depolymerizing factor homolog 2
Rhoptry-associated leucine zipper-like protein 1
No activity. The mutant forms hexamers instead of dodecamers.
No activity; when associated with A-136 and A-139.
No activity; when associated with A-136 and A-140.
No effect on dodecamer assembly. No activity; when associated with A-139 and A-140.
Pyridoxal 5'-phosphate synthase subunit Pdx1
Schiff-base intermediate with D-ribose 5-phosphate
Probable ATP-dependent helicase PF08_0048
Pentatricopeptide repeat-containing protein 1, apicoplast
Glycyl lysine isopeptide (Gly-Lys) (interchain with K-? in acceptor proteins)
Reticulocyte-binding protein homolog 2a 285 kDa form
Reticulocyte-binding protein homolog 2a 85 kDa form
Translation factor GUF1 homolog, mitochondrial
Putative 50S ribosomal protein L18, apicoplastic
Slight reduction in catalytic efficiency towards a synthetic peptide.
Peptidyl-prolyl cis-trans isomerase FKBP35
Severe loss of binding to a HSP90 C-terminus peptide (MEEVD).
Dual specificity protein phosphatase YVH1
Phosphatidylserine amidated glycine; alternate
No effect on lipoylation of BCKDH-E2/BCDH and KDH in the presence of LipL1.
Vacuolar protein sorting-associated protein 26
Probable DNA-directed RNA polymerase II subunit RPB11
Schiff-base intermediate with dihydroxyacetone-P
Pyridoxal 5'-phosphate synthase subunit PDX2
Mislocalizes to the cytoplasm. Mislocalizes to the cytoplasm; when associated with A-4.
Partial mislocalization to the cytoplasm with some localization to the cell membrane. Mislocalizes to the cytoplasm; when associated with A-2.
Remains associated with the cytoplasmic side of the cell membrane with no translocation across the cell membrane.
Ubiquinone biosynthesis protein COQ4 homolog, mitochondrial
SUEL-type lectin domain-containing protein
Probable U3 small nucleolar RNA-associated protein 11
Fewer and larger knobs. No EMP1 at the erythrocyte cell surface. Increase in the number of vesicles at the Maurer's clefts. PTP7 appears to be mislocalized.
No significant effect on knob density and knob diameter. 32-percent reduction in EMP1 at the erythrocyte cell surface.
Slight decrease in knob density and slight increase in knob diameter. 65-percent reduction in EMP1 at the erythrocyte cell surface. PTP7 appears to be mislocalized.
Parasitophorous vacuole membrane protein S16
Virus assembly crescent formation protein
Basic cluster involved in membrane binding
Does not affect myristoylation. Severe reduction in membrane binding. Loss of membrane binding; when associated with V-2.
J domain interacts with the EF-hand domains
Loss of myristoylation. Severe reduction in membrane binding. Loss of membrane binding; when associated with 10-K--T-20 DEL.
Loss of phosphorylation. Loss of catalytic activity.
Loss of phosphorylation. No effect on catalytic activity.
Phospho-mimetic mutant.No effect on catalytic activity.
Phosphothreonine; by PKG; by autocatalysis
Severe loss of ATP binding. Partial loss of catalytic activity.
Dihydroorotate dehydrogenase (quinone), mitochondrial
DNA-(apurinic or apyrimidinic site) endonuclease
3'-phosphate/5'-hydroxy nucleic acid ligase
Loss of myristoylation. Loss of myristoylation; when associated with A-3.
Loss of myristoylation; when associated with A-2.
ATP-dependent Clp protease proteolytic subunit
Trafficking protein particle complex subunit 5
12-fold reduction in affinity for TRX1 and 25-fold decrease in catalytic efficiency.
7-fold reduction in affinity for TRX1 and 16-fold decrease in catalytic efficiency.
No effect on affinity for TRX1 and 2-fold decrease in catalytic efficiency.
11-fold reduction in affinity for L-arginine. Loss of oligomerization.
2.5-fold decrease in affinity for L-arginine.
3.4-fold reduction in affinity for L-arginine. Loss of oligomerization.
Loss of catalytic activity and loss of oligomerization; when associated with A-323.
Loss of catalytic activity and loss of oligomerization; when associated with A-325.
Loss of catalytic activity. Loss of oligomerization.
Loss of catalytic activity. No defect in oligomerization.
Severe loss of catalytic activity. Loss of oligomerization.
Severe loss of catalytic activity. Oligomerization is partially reduced.
Bifunctional glucose-6-phosphate 1-dehydrogenase/6-phosphogluconolactonase
Loss of catalytic activity and auto-phosphorylation.
Loss of catalytic activity in absence or in presence of calcium.
No effect on catalytic activity and auto-phosphorylation.
No effect on catalytic activity. Is active in absence of calcium.
Partial loss of catalytic activity in presence of calcium.
Partial loss of catalytic activity. Is active in absence of calcium.
Increases catalytic activity. Slightly decreases affinity for NADPH.
Strongly decreases catalytic activity. Abolishes NADPH binding.
Eukaryotic translation initiation factor 2-alpha kinase 1
proton-translocating NAD(P)(+) transhydrogenase
4-hydroxy-3-methylbut-2-enyl diphosphate reductase, apicoplast
Decreases sensitivity towards inhibitors.
cGMP-specific 3',5'-cyclic phosphodiesterase delta
Glyco_hydro_35 domain-containing protein
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase beta
Ephrin_rec_like domain-containing protein
Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
Impairs homodimerization. 30-fold decrease in catalytic activity without affecting affinity for substrate 2-phosphoglyceric acid. Decreases affinity for Mg(2+).
No effect on homodimerization. Decreases catalytic activity without affecting affinity for substrate 2-phosphoglyceric acid. Loss of Mg(2+) binding.
Reduces homodimerization efficiency. Decreases catalytic activity without affecting affinity for substrate 2-phosphoglyceric acid. Loss of Mg(2+) binding.
Small increase in deubiquitinating and deneddylating activities. Small reduction in deubiquitinating and deneddylating activities; when associated with E-33.
Small reduction in deubiquitinating and deneddylating activities. Small reduction in deubiquitinating and deneddylating activities; when associated with D-13.
Ubiquitin carboxyl-terminal hydrolase UCHL3
Coiled-coil domain-containing protein PF3D7_1144200
Leucine-rich repeat and coiled-coil domain-containing protein PF3D7_0703800
Acidic leucine-rich nuclear phosphoprotein 32-related protein
About 70% reduction in catalytic activity. Does not affect TRX1-mediated activation.
No effect on catalytic activity. Requires higher concentrations of TRX1 for activation. Severe reduction in catalytic activity and loss of TRX1-mediated activation; when associated with S-154.
Severe reduction in catalytic activity. Does not affect TRX1-mediated activation. Severe reduction in catalytic activity and loss of TRX1-mediated activation; when associated with S-163.
Glycerol-3-phosphate dehydrogenase [NAD(+)]
5-fold increase in inorganic phosphate (Pi) release in presence of Mg(2+).
Fail to form long filaments. No inorganic phosphate (Pi) release in presence of Ca(2+). Increases Pi release in presence of Mg(2+). No effect of K(+) on Pi release.
Failure to form long filaments. Inorganic phosphate (Pi) release is slightly better in presence of Ca(2+) than Mg(2+). Slight decrease in inorganic phosphate (Pi) release rates in presence of Mg(2+) or Mg(2+) and K(+).
Forms longer filaments. 18.9-fold increase in inorganic phosphate (Pi) release in presence of Mg(2+). Filament elongation rate is normal.
Forms longer filaments. Increased inorganic phosphate (Pi) release in presence of Mg(2+) which is further increased in presence of K(+). Filament elongation rate is normal.
Increases inorganic phosphate (Pi) release in presence of Mg(2+). No effect of K(+) on Pi release. No effect on Pi release in absence or in presence of K(+); when associated with Q-42.
No formation of long filaments. Reduces inorganic phosphate (Pi) release. No effect of Mg(2+) or K(+) on Pi release. Filament elongation rate appears normal.
Reduces inorganic phosphate (Pi) release in presence of Mg(2+). No effect of K(+) on Pi release. No effect on Pi release in absence or in presence of K(+); when associated with G-49.
GRIP and coiled-coil domain-containing protein
cGMP-specific 3',5'-cyclic phosphodiesterase alpha
Structural maintenance of chromosomes protein 2
1300-fold decrease in catalytic efficiency for inosine as substrate. Loss of catalytic activity towards 5'-methylthioinosine.
17300-fold decrease in catalytic efficiency with inosine as substrate. Reduced affinity for DADMe-ImmG inhibitor.
20-fold decrease in affinity for inosine. Loss of catalytic activity towards 5'-methylthioinosine.
200-fold decrease in catalytic efficiency with inosine as substrate. Loss of catalytic activity towards 5'-methylthioinosine.
23-fold decrease in catalytic efficiency for inosine as substrate. Slight decrease in catalytic efficiency for 5'-methylthioinosine as substrate.
4-fold decrease in catalytic efficiency with inosine as substrate. Reduced affinity for DADMe-ImmG inhibitor.
40-fold decrease in catalytic efficiency with inosine as substrate. Loss of catalytic activity towards 5'-methylthioinosine.
680-fold decrease in catalytic efficiency with inosine as substrate. 200-fold decrease in catalytic efficiency with 5'-methylthioinosine as substrate.
790-fold decrease in catalytic efficiency for inosine as substrate. 4000-fold decrease in catalytic efficiency for 5'-methylthioinosine as substrate.
8-fold decrease in catalytic efficiency with inosine as substrate. Slight increase in catalytic efficiency with 5'-methylthioinosine as substrate.
Loss of catalytic activity towards inosine and 5'-methylthioinosine.
No effect on catalytic activity towards inosine or 5'-methylthioinosine; when associated with I-66. 20-fold decrease in catalytic efficiency with 5'-methylthioinosine as substrate and no effect on catalytic activity towards inosine; when associated with F-160. 170-fold decrease in catalytic efficiency with 5'-methylthioinosine as substrate and no effect on catalytic activity towards inosine; when associated with I-66 and F-160.
No effect on catalytic activity towards inosine or 5'-methylthioinosine; when associated with I-73. 20-fold decrease in catalytic efficiency with 5'-methylthioinosine as substrate and no effect on catalytic activity towards inosine; when associated with F-160. 170-fold decrease in catalytic efficiency with 5'-methylthioinosine as substrate and no effect on catalytic activity towards inosine; when associated with I-73 and F-160.
No effect on catalytic activity towards inosine. 14-fold decrease in catalytic efficiency with 5'-methylthioinosine as substrate. 20-fold decrease in catalytic efficiency with 5'-methylthioinosine as substrate; when associated with I-66 or I-73. 170-fold decrease in catalytic efficiency with 5'-methylthioinosine as substrate and no effect on catalytic activity towards inosine; when associated with I-66 and I-73.
No effect on catalytic activity towards inosine. Slight increase in catalytic efficiency with 5'-methylthioinosine as substrate.
Slight decrease in catalytic activity towards inosine and 5'-methylthioinosine.
Slight decrease in catalytic activity towards inosine. Slight increase in catalytic activity towards 5'-methylthioinosine.
Slight decrease in catalytic efficiency with inosine as substrate. 8500-fold decrease in catalytic efficiency with 5'-methylthioinosine as substrate.
Slight decrease in catalytic efficiency with inosine or 5'-methylthioinosine as substrates.
Putative histone-lysine N-methyltransferase 1
Eukaryotic translation initiation factor 2 subunit 1
Loss of phosphorylation by eIK1. Loss of interaction with phosphatase IUS2.
Phosphomimetic mutant. No effect on the interaction with phosphatase IUS2.
MATH and LRR domain-containing protein PFE0570w
10-fold decrease in substrate affinity and 20-fold decrease in activity.
3-fold decrease in substrate affinity and 2-fold decrease in activity.
Greater than 10-fold decrease in activity.
Reticulocyte-binding protein homolog 1 120 kDa form
Reticulocyte-binding protein homolog 1 240 kDa form
3-hydroxyacyl-[acyl-carrier-protein] dehydratase
Plasmodium-specific profilin mini-domain
Loss of N-glycosylation; when associated with D-145 and D-322.
Loss of N-glycosylation; when associated with D-145 and D-338.
Loss of N-glycosylation; when associated with D-322 and D-338.
Prevents the interaction with c2 neutralizing antibodies.
Dipeptidyl aminopeptidase 1 exclusion domain chain
No effect on homotrimerization and stability. Slight reduction in protein stability; when associated with A-191.
No effect on homotrimerization and stability. Slight reduction in protein stability; when associated with F-213.
Variant-silencing SET domain-containing protein
Plasmodium variant antigen protein Cir/Yir/Bir
2.5-fold reduction in affinity for dTMP. 2.6-fold reduction in affinity for dGMP.
4 to 5-fold decrease in affinity for dTMP and dGMP. 6-fold decrease in catalytic efficiency with dTMP as substrate. 65-fold decrease in catalytic efficiency with dGMP as substrate.
8-fold decrease in affinity for dTMP. 4-fold decrease in affinity for dGMP. 439-fold decrease in catalytic efficiency with dGMP as substrate.2000-fold decrease in catalytic efficiency with dGMP as substrate.
Loss of thymidylate and guanylate kinase activities.
No defect in thymidylate kinase activity. 1.3-fold reduction in affinity for dGMP.
No defect in thymidylate kinase activity. 2.1-fold reduction in affinity for dGMP.
12% reduction in cGMP-mediated catalytic activity. Slight reduction in cGMP-mediated catalytic activity; when associated with A-133. Severe loss of cGMP-mediated catalytic activity; when associated with A-493 or A-133 and A-493.
4.5-fold reduction in affinity for ATP. No defect in schizogony during host erythrocyte invasion. However, Ca(2+) increase in response to cGMP is reduced in schizonts. Does not affect merozoite egress from host erythrocytes. Resistant to trisubstituted pyrrole compound 1 (C1) and imidazopyridine-based compound 2 (C2) inhibitors.
42% reduction in cGMP-mediated catalytic activity. Severe loss of cGMP-mediated catalytic activity; when associated with A-133, A-251 or A-133 and A-251.
55% loss in cGMP-mediated catalytic activity.
Has low catalytic activity in absence of cGMP.
Has low catalytic activity in absence of cGMP. Normal increase in catalytic activity in presence of cGMP.
Has low catalytic activity in absence of cGMP. cGMP binding is still required for full activation.
Loss of catalytic activity and irresponsive to cGMP, with peptides as substrates.
Low basal catalytic activity. Normal increase in catalytic activity in presence of cGMP.
No effect on cGMP-mediated catalytic activity. Slight reduction in cGMP-mediated catalytic activity; when associated with A-251. Severe loss of cGMP-mediated catalytic activity; when associated with A-493 or A-251 and A-493.
Reduces affinity for cGMP and severe loss of kinase activity.
V-type proton ATPase catalytic subunit A
Eukaryotic translation initiation factor 2-alpha kinase PK4
Loss of apurinic/apyrimidinic (AP) endonuclease activity.
Loss of apurinic/apyrimidinic (AP) endonuclease activity. Loss of Mn(2+) binding. Impairs DNA binding.
1-deoxy-D-xylulose 5-phosphate reductoisomerase, apicoplastic
Pentatricopeptide repeat-containing protein 2
Cofilin/actin-depolymerizing factor homolog 1
Does not stably interact with OAT and fails to increase OAT catalytic activity; when associated with S-33 or S-30 and S-33.
Does not stably interact with OAT and fails to increase OAT catalytic activity; when associated with S-33 or S-33 and S-43. Does not stably interact with SAHH; when associated with S-33.
Forms a stable disulfide intermediate with OAT. Fails to increase OAT catalytic activity. Does not stably interact with OAT and fails to increase OAT catalytic activity; when associated with S-30 and/or S-43. Forms a stable disulfide intermediate with SAHH. Does not stably interact with SAHH; when associated with S-30.
Loss of catalytic activity. Blood stage parasites are not viable.
2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase, apicoplast
No effect on catalytic activity. Active in both reducing and non-reducing conditions.
Severe loss of catalytic activity characterized by a severe loss in substrate affinity.
Liver stage-specific antigen-related protein
Gly-cisPro motif, allows the protein to recognize chirality of D-amino acids
Loss of deacylation of D-tyrosyl-tRNA(Tyr), loss of deacylation of glycyl-tRNA(Gly), not toxic upon overexpression.
Loss of deacylation of D-tyrosyl-tRNA(Tyr), loss of deacylation of glycyl-tRNA(Gly).
Loss of deacylation of D-tyrosyl-tRNA(Tyr).
Partial loss of deacylation of D-tyrosyl-tRNA(Tyr).
Wild-type deacylation of D-tyrosyl-tRNA(Tyr).
Lacks protease activity. No cellular location and growth defects in host red blood cells.